一分钟看懂
这是一项关于结直肠癌的II 期 / III 期研究,登记的药物或干预包括Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart;Irinotecan liposome + 5-FU/LV + Bevacizumab;Irinotecan + 5-FU/LV + Bevacizumab,当前状态为尚未开始招募。登记地点显示中国石家庄有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart;Irinotecan liposome + 5-FU/LV + Bevacizumab;Irinotecan + 5-FU/LV + Bevacizumab · II 期 / III 期
登记条件中文摘要
年龄范围:18岁至75岁
登记的基本范围为不限性别,年龄18岁至75岁;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Fourth Hospital of Hebei Medical University · 石家庄
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- 1. Aged ≥ 18 years old and ≤ 75 years old.
- 2. Histologically or cytologically confirmed metastatic colon or rectal adenocarcinoma;
- 3. Patients must have at least one measurable lesion according to RECIST 1.1 criteria.
- 4. Had received first-line treatment based on oxaliplatin.
- 5. Eastern Cooperative Oncology Group performance status score of 0, 1, or 2;
- 6. Expected survival time ≥3 months.
- 7. Adequate organ function, meeting the following laboratory test standards:
- 1\) Bone marrow function: Neutrophils≥1.5×109/L, Platelets≥100×109/L, Hemoglobin≥90 g/L, White blood cells ≥3.0×109/L; 2) Liver function:Alanine aminotransferase, Aspartate aminotransferase, Alkaline phosphatase≤2.5×upper limit of normal (ULN), when there is liver metastasis, ≤ 5×ULN; Total bilirubin≤1.5×ULN; 3) Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance rate ≥ 60 ml/min, Urine protein≤2+; 4) Coagulation function: Activated partial thromboplastin time and International Normalized Ratio ≤1.5 × ULN; 5) Thyroid function: Thyroid stimulating hormone≤ULN; If abnormal, additional tests for FT3 and FT4 should be conducted and their levels should be normal; 6) Albumin≥3 g/dL; 8. Pregnant women of childbearing age with negative pregnancy test and non-lactating, participants with reproductive capacity must receive effective contraceptive measures; 9. Patients and/or legal representative must have the ability to understand and voluntarily sign a written informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT07585279;登记信息更新于 2026-05-13;本站同步于 2026-11-21。